Study of the way unevenness in lung function changes with treatment in airways disease

How are non-invasive measures of lung inhomogeneity affected during treatment of airways disease?

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12223638

Enrollment

150

Registered

2019-05-10

Start date

2018-06-25

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airways disease Respiratory

Interventions

Current interventions as of 07/12/2022: This is an observational study in which indices of lung heterogeneity are measured in patients with airways disease. Patients will be studied at baseline and on

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years 2. Diagnosis of airways disease

Exclusion criteria

Exclusion criteria: 1. Inability to tolerate mouthpiece/nose-clip 2. Pregnancy

Design outcomes

Secondary

Measure	Time frame
1. Correlation between baseline lung heterogeneity indices and other clinical markers of disease e.g. FeNO, blood eosinophil count, sputum eosinophil count, FEV1, FEV1/FVC ratio and ACQ5 score. 2. Correlation between changes in lung heteroegeneity indices and changes in other clinical markers of disease measured using FeNO, blood eosinophil count, sputum eosinophil count, FEV1, FEV1/FVC ratio and ACQ5 score before and after treatment (1 week, 5 weeks and 3 months).	—

Measure

Time frame

1. Correlation between baseline lung heterogeneity indices and other clinical markers of disease e.g. FeNO, blood eosinophil count, sputum eosinophil count, FEV1, FEV1/FVC ratio and ACQ5 score. 2. Correlation between changes in lung heteroegeneity indices and changes in other clinical markers of disease measured using FeNO, blood eosinophil count, sputum eosinophil count, FEV1, FEV1/FVC ratio and ACQ5 score before and after treatment (1 week, 5 weeks and 3 months).

—

Primary

Measure	Time frame
Change in lung heterogeneity indices following treatment (pre-treatment baseline, and then 1 week, 5 weeks and/or 3 months post-treatment, depending on the treatment given). The indices are measured during the lung heterogeneity test: sCL:VA (standard deviation of the compliance:volume distribution), sVD:VA (standard deviation of the deadspace:volume distribution) and VDtot/VAtot (ratio of total deadspace to total alveolar volume).	—

Measure

Time frame

Change in lung heterogeneity indices following treatment (pre-treatment baseline, and then 1 week, 5 weeks and/or 3 months post-treatment, depending on the treatment given). The indices are measured during the lung heterogeneity test: sCL:VA (standard deviation of the compliance:volume distribution), sVD:VA (standard deviation of the deadspace:volume distribution) and VDtot/VAtot (ratio of total deadspace to total alveolar volume).

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026